Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 21 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-2.01 Insider Own51.45% Shs Outstand40.61M Perf Week-12.82%
Market Cap42.37M Forward P/E- EPS next Y-1.03 Insider Trans0.00% Shs Float20.17M Perf Month-28.17%
Income-81.22M PEG- EPS next Q-0.30 Inst Own17.11% Short Float7.06% Perf Quarter-59.36%
Sales15.07M P/S2.81 EPS this Y52.05% Inst Trans-32.33% Short Ratio7.75 Perf Half Y-65.77%
Book/sh0.26 P/B3.89 EPS next Y16.91% ROA-70.64% Short Interest1.42M Perf Year-87.58%
Cash/sh1.36 P/C0.75 EPS next 5Y- ROE-167.51% 52W Range0.99 - 9.77 Perf YTD-65.19%
Dividend Est.- P/FCF- EPS past 5Y24.98% ROI-559.22% 52W High-89.56% Beta1.50
Dividend TTM- Quick Ratio4.64 Sales past 5Y25.00% Gross Margin65.59% 52W Low3.03% ATR (14)0.10
Dividend Ex-Date- Current Ratio4.64 EPS Y/Y TTM47.72% Oper. Margin-565.71% RSI (14)32.03 Volatility7.04% 8.40%
Employees107 Debt/Eq0.69 Sales Y/Y TTM-65.14% Profit Margin-538.81% Recom1.40 Target Price7.60
Option/ShortNo / Yes LT Debt/Eq0.33 EPS Q/Q75.95% Payout- Rel Volume0.95 Prev Close1.01
Sales Surprise-22.71% EPS Surprise-6.36% Sales Q/Q4.75% EarningsMay 09 BMO Avg Volume183.75K Price1.02
SMA20-15.84% SMA50-30.01% SMA200-59.87% Trades Volume174,063 Change0.99%
Date Action Analyst Rating Change Price Target Change
Apr-11-24Initiated BTIG Research Buy $6
Oct-03-23Initiated CapitalOne Overweight $10
Jul-06-23Initiated Evercore ISI Outperform $12
May-31-23Upgrade Jefferies Hold → Buy $0.60 → $7
May-24-23Initiated H.C. Wainwright Buy $10
Apr-14-23Initiated Robert W. Baird Outperform $10
Jun-13-24 04:30PM
May-30-24 07:30AM
May-16-24 07:30AM
May-09-24 01:54PM
07:30AM Loading…
May-08-24 07:30AM
May-06-24 07:30AM
May-02-24 10:01AM
Apr-24-24 05:05PM
Apr-22-24 04:35PM
Apr-04-24 09:55AM
Apr-03-24 07:00AM
Apr-01-24 01:53PM
08:35AM Loading…
Mar-21-24 05:00PM
Feb-28-24 07:30AM
Dec-21-23 07:00AM
Dec-14-23 07:00AM
Nov-28-23 07:00AM
Nov-22-23 07:30AM
Nov-09-23 07:30AM
Oct-31-23 09:25AM
Oct-25-23 09:11AM
Oct-12-23 02:52PM
Sep-05-23 08:30AM
Sep-01-23 08:30AM
Aug-24-23 08:30AM
09:55AM Loading…
Aug-23-23 09:55AM
Aug-13-23 08:07AM
Aug-10-23 07:30AM
Jul-19-23 06:34AM
Jun-28-23 08:30AM
Jun-26-23 08:30AM
Jun-14-23 08:30AM
Jun-08-23 01:11PM
Jun-05-23 07:30AM
May-30-23 04:30PM
May-11-23 07:30AM
May-08-23 04:30PM
May-05-23 04:30PM
Apr-14-23 12:51PM
Apr-06-23 04:30PM
Apr-04-23 08:30AM
Mar-20-23 02:04PM
Carisma Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of immunotherapies. It offers chimeric antigen receptor (CAR)-macrophages, a cell therapy platform focusing on the treatment of solid tumors. The company was founded by Michael Klichinsky and Saar Gill in 2016 and is headquartered in Philadelphia, PA.